Outcomes and Treatment of Chronic Methicillin-Resistant *Staphylococcus aureus* Differs by Staphylococcal Cassette Chromosome *mec* (SCCmec) Type in Children With Cystic Fibrosis

Sonya L. Heltshe,1,2 Lisa Saiman,3,4 Elena B. Popowitch,5,6 Melissa B. Miller,5,6 Margaret Kloster,2 Valeria Thompson,2 Thomas W. Ferkol,7,8 Wynton C. Hoover,9 Michael S. Schechter,10, a and Marianne S. Muhlebach11

1Division of Pediatric Pulmonology, Department of Pediatrics, University of Washington School of Medicine, Seattle; 2Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, Seattle Children’s Research Institute, Washington; 3Department of Pediatrics, Columbia University Medical Center, New York; 4Department of Infection Prevention & Control, New York-Presbyterian Hospital; Departments of 5Medicine and, 6Microbiology and Immunology, University of North Carolina at Chapel Hill; Departments of 7Pediatrics, 8Genetics, Washington University, St. Louis, Missouri; 9Department of Pediatrics, University of Alabama at Birmingham; 10Emory University School of Medicine, Atlanta, Georgia; and 11Division of Pediatric Pulmonology, Department of Pediatrics, University of North Carolina at Chapel Hill

**Corresponding Author:** Marianne S. Muhlebach, MD, 450 MacNider, 333 S. Columbia Street, CB #7217, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599–7217. E-mail: Marianne_Muhlebach@med.unc.edu.

**Present Affiliation:** Division of Pediatric Pulmonary Medicine, Children’s Hospital of Richmond at Virginia Commonwealth University, Richmond, Virginia.

**STAR-CF Study Team—listed alphabetically by CF center, * denotes authors who fully meet the criteria for authorship:** Children’s Hospital of Pittsburgh, Pennsylvania-Daniel J Weiner, MD; Columbia University, New York-Lynne Quittell, MD; Emory University, Georgia-Michael Schechter*, MD, MPH (MS relocated to VA); Riley Hospital for Children, Indiana-Michelle Howenstine, MD; St. Louis Children’s Hospital, Missouri-Thomas Ferkol*, MD; University of Alabama at Birmingham, Alabama-Wynton Hoover*, MD; University of North Carolina at Chapel Hill, North Carolina-Marianne Muhlebach*, MD

Received February 20, 2014; accepted April 30, 2014; electronically published June 9, 2014.

**Background.** Methicillin-resistant *Staphylococcus aureus* (MRSA) infects ~25% of patients with cystic fibrosis (CF) in the United States. We hypothesized that health-related outcomes differed between healthcare-associated (staphylococcal cassette chromosome *mec* [SCCmec] II) vs community-associated (SCCmec IV) MRSA strains in patients chronically infected with CF.

**Methods.** At 7 CF centers, MRSA isolates were prospectively obtained from patients ≤18 years old with 2 or more positive MRSA cultures within 1 year. Isolates were classified by SCCmec type and Panton-Valentine-leukocidin (PVL) status at a core laboratory, and sites remained blinded to SCCmec type and PVL results. Prospective clinical data including antibiotic use, respiratory symptoms, and pulmonary exacerbations were obtained.

**Results.** Among the 295 cohort participants with typeable MRSA isolates, 69.5% had SCCmec II PVL(−), 13.2% had SCCmec IV PVL(−), and 17.3% had SCCmec IV PVL(+) strains. During follow-up of 287 patients with prospective data after enrollment, the risk for pulmonary exacerbations was significantly higher among participants with SCCmec II than SCCmec IV strains (risk ratio [RR] = 1.13; *P* = .03) and higher in those with SCCmec IV PVL(−) than SCCmec IV PVL(+) strains (RR = 1.62; *P* < .0001). Neither decline in lung function nor changes in nutritional outcomes differed by SCCmec type or PVL status during the study period.

**Conclusions.** Participants harboring chronic SCCmec II MRSA received more antibiotics and may have more lung disease than those with SCCmec IV; PVL(+) isolates were not associated with more advanced disease.

**Key words.** cystic fibrosis; methicillin-resistant *Staphylococcus aureus*; Panton-Valentine leukocidin; pulmonary exacerbation; PVL; SCCmec type.
BACKGROUND

The incidence and prevalence of methicillin-resistant *Staphylococcus aureus* (MRSA) has been increasing in patients with cystic fibrosis (CF) in the United States. By 2010, 25.8% of patients reported to the Cystic Fibrosis Foundation National Patient Registry had a positive respiratory culture for MRSA [1, 2]. Epidemiologic studies performed in patients with CF have suggested that lung function may be lower with MRSA compared to methicillin-susceptible *S. aureus*, and chronic MRSA infection is associated with increased mortality [3–5] and morbidity [6].

Methicillin resistance is encoded by the staphylococcal cassette chromosome mec (SCCmec) gene complex. In general, healthcare-associated strains carry SCCmec types I–III and are negative for Panton-Valentine leukocidin (PVL), whereas strains more likely to be community-associated carry the smaller SCCmec IV–V elements [7–9]. However, SCCmec types II and IV are increasingly found in community and hospital settings, respectively [10–12]. Studies evaluating the molecular epidemiology of MRSA in patients with CF in the United States have reported approximately two-thirds of MRSA strains were SCCmec II [13–15]. In non-CF MRSA disease, outcomes may be different based on SCCmec status [16, 17]. However, outcomes associated with different SCCmec types have not been addressed in CF patients with chronic lung infections, and SCCmec status is not currently used in clinical care. Nonetheless, because SCCmec II encodes for more antibiotic resistance genes [18, 19], there may be a poor response to oral antibiotics or choices may be limited; thus, the question arises whether knowledge of the SCCmec type would be relevant to care.

We hypothesized that, among children with CF who are chronically infected with MRSA, outpatient antibiotic use, exacerbations, and lung function and growth metrics would differ by SCCmec type and that PVL(+) isolates would be associated with worse outcomes. We present a multicenter observational study to evaluate the clinical outcomes and treatment associated with different SCCmec types and PVL status in children with CF who have persistently MRSA-positive respiratory tract cultures.

METHODS

Study Design, Participants, and Sites

An observational study was conducted at 7 CF centers from different regions of the United States between 2008 and 2012. Patients diagnosed with CF [20], ≤18 years of age, with chronic MRSA infection (≥2 positive cultures within at least 1 of the 2 years before enrollment) were eligible. They were included in the study if their culture was positive for MRSA at enrollment or at 1 of the 2 subsequent CF clinic visits. Patients who had positive cultures for *Burkholderia cepacia* complex or had undergone lung transplantation were ineligible to participate. Sites were selected based on MRSA prevalence (>20%) and size (>200 pediatric patients). The study was approved by each center’s Institutional Review Board, written consent was obtained from parents, and assent was obtained from children able to read.

Typing of MRSA Isolates

Participants’ respiratory cultures (deep pharyngeal swab, sputum, or bronchoalveolar lavage) were processed at each site’s clinical microbiology laboratory using the Cystic Fibrosis Foundation’s guidelines [21]. Three colonies of MRSA from the same culture were sent to the core laboratory at the University of North Carolina to determine the SCCmec type and presence of the PVL gene using polymerase chain reaction methods previously described [15, 22, 23]. Treating physicians were not informed about the typing results.

Data Collection

Site investigators prospectively recorded each participant’s clinic visits from patient entry into the study until April 2012 or for a maximum of 3 years of follow-up. Weight, height, spirometry as forced expiratory volume in 1 second (FEV1), and respiratory tract culture results were recorded at visits when new antibiotics were prescribed (oral, inhaled, or intravenous [IV]) for respiratory indications. Spirometry was recorded for those participants older than 6 years of age and expressed as percentage predicted per Wang’s equation [24]. Body mass index (BMI) percentile (in participants 2 years of age or older) or weight for length percentile (in participants less than 2 years of age) according to US standards [25, 26] were recorded. Organisms other than *S. aureus* present in the respiratory tract cultures were collected, but antibiotic susceptibility patterns were not recorded for any CF pathogens. Antibiotic use was collected for oral, inhaled, and IV antibiotics. Oral antimicrobial agents included trimethoprim-sulfamethoxazole (TMP-SMX), fluoroquinolone agents, linezolid, tetracycline, rifampin, clindamycin, and other agents without activity against MRSA (eg, amoxicillin).

The presence of specific signs and symptoms were collected at the time of prescribing a new antibiotic to evaluate whether the event qualified as a study-defined pulmonary exacerbation [27, 28]. In brief, an exacerbation was defined as receiving new antibiotic treatment plus 1 or 2 of the 2 major criteria (≥10% decrease in FEV1 from 6-month baseline, or oxygen saturation <90%, or 5% decline) or...
RESULTS

From October 2008 to April 2010, 314 MRSA-positive patients with a history of chronic MRSA infection were recruited from 7 CF centers. Of these, 295 participants had typeable MRSA isolates: 205 (69.5%) SCCmec II all PVL (−), 39 (13.2%) SCCmec IV PVL(−), and 51 (17.3%) SCCmec IV PVL(+). The final study population consisted of 287 participants for whom the date of first detection of MRSA was available in the Cystic Fibrosis Patient Registry, and prospective study data were collected.

Participant Characteristics by MRSA Type

Mean age, sex, CFTR genotypes, lung function (FEV₁% predicted), and nutritional status (BMI or weight for length percentile) were similar in participants with SCCmec II vs SCCmec IV MRSA type and among those with SCCmec IV PVL(+) and SCCmec IV PVL(−) isolates (Table 1). However, there were more participants ≥12 years of age infected with SCCmec II isolates. A greater percentage of participants with SCCmec II isolates had Pseudomonas aeruginosa-positive cultures at study enrollment (30.2% compared to 19.3% in SCCmec type IV), but the difference was not statistically significant (P = .056).

Most (71%) of the participants had 2 or more years of prospective follow-up; 91% (n = 261) had 1 year or more of follow-up, and 3.8% (n = 11) had only data collected during the enrollment visit. Duration of follow-up was comparable for participants with SCCmec II and SCCmec IV (mean [standard deviation; SD] = 2.2 [0.71] vs 2.1 [0.75] years, respectively; P = .15). At the time of enrollment, participants with SCCmec II had significantly longer duration of MRSA infection than those with SCCmec IV (mean = 4.7 [3.1] and 3.1 [2.5] years,

Table 1. Participant Characteristics by MRSA Type at Time of Study Enrollment

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>SCCmec II N = 199</th>
<th>SCCmec IV N = 88</th>
<th>P Value</th>
<th>SCCmec IV PVL(+) N = 50</th>
<th>SCCmec IV PVL(−) N = 38</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n (%)</td>
<td>102 (51.3%)</td>
<td>37 (42.1%)</td>
<td>0.16</td>
<td>21 (42.0%)</td>
<td>16 (42.1%)</td>
<td>1.0</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>11.5 (4.6)</td>
<td>10.3 (5.0)</td>
<td>0.40</td>
<td>10.0 (5.2)</td>
<td>10.7 (4.6)</td>
<td>0.41</td>
</tr>
<tr>
<td>Age group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;6 years</td>
<td>31 (15.6%)</td>
<td>16 (18.2%)</td>
<td>0.03*</td>
<td>11 (22.0%)</td>
<td>5 (13.2%)</td>
<td>0.63*</td>
</tr>
<tr>
<td>6–11 years</td>
<td>65 (32.7%)</td>
<td>41 (46.6%)</td>
<td>22 (44.0%)</td>
<td>19 (50.0%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥12 years</td>
<td>103 (51.8%)</td>
<td>31 (35.2%)</td>
<td>17 (34.0%)</td>
<td>14 (36.8%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CFTR genotype</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F508 del homozygous</td>
<td>113 (56.8%)</td>
<td>43 (48.9%)</td>
<td>0.52*</td>
<td>27 (54.0%)</td>
<td>16 (42.1%)</td>
<td>0.39*</td>
</tr>
<tr>
<td>F508 del heterozygous</td>
<td>71 (35.7%)</td>
<td>36 (40.9%)</td>
<td>18 (36.0%)</td>
<td>18 (47.4%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>10 (5.0%)</td>
<td>7 (8.0%)</td>
<td>3 (6.0%)</td>
<td>4 (10.5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pseudomonas aeruginosa</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n (%)</td>
<td>60 (30.2%)</td>
<td>17 (19.3%)</td>
<td>0.056</td>
<td>12 (24.0%)</td>
<td>5 (13.2%)</td>
<td>0.20</td>
</tr>
<tr>
<td>BMI or Wt/length Percentile‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n: mean (SD)</td>
<td>176: 44.3 (27.3)</td>
<td>79: 46.4 (29.8)</td>
<td>0.34</td>
<td>44: 41.2 (30.1)</td>
<td>35: 53.0 (28.5)</td>
<td>0.75</td>
</tr>
<tr>
<td>FEV₁% predicted§</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n: mean (SD)</td>
<td>141: 81.9 (22.0)</td>
<td>64: 81.7 (22.5)</td>
<td>0.82</td>
<td>34: 77.9 (22.7)</td>
<td>30: 85.9 (21.9)</td>
<td>0.16</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index; CFTR, cystic fibrosis transmembrane regulator; FEV₁, forced expiratory flow in 1 second; MRSA, methicillin-resistant Staphylococcus aureus; PVL, Panton-Valentine-leukocidin; SCCmec, staphylococcal cassette chromosome mec; SD, standard deviation; Wt/length, weight for length.

*P value for Fisher’s test of distributional differences between groups.
‡For children <2 years of age, weight for length is used in place of BMI.
§FEV₁% predicted is recorded only in participants >6 years of age (see Methods).
respectively; \( P < .001 \)). Among those with SCCmec IV isolates, the duration of time since initial detection of MRSA was longer in those with PVL(-) isolates (mean = 4.0 [3.0] years) than PVL(+) isolates (mean = 2.4 [1.9] years) (\( P < .01 \)).

### Clinic Visits and Antibiotic Treatment
The number of CF clinic visits and the rate of antibiotic prescriptions by SCCmec type and PVL status are described in Table 2. For all participants with MRSA, the mean number of clinic visits was 6.0 (SD = 2.9) visits per year and ranged from 1 to 62 clinic visits per participant during the study period. Participants with SCCmec IV PVL(-) isolates had more CF clinic visits per participant and per year of follow-up than those with SCCmec IV PVL(+) isolates.

Antibiotics (oral, additional inhaled or IV) were prescribed at 58.1% of all CF clinic visits in association with increased signs and symptoms. Oral agents were most common and were prescribed at 45.8% of visits (46.9% of visits of participants with SCCmec II isolates compared to 42.9% of visits of participants with SCCmec IV isolates; \( P = .025 \)). Overall, the oral antibiotics TMP-SMX, fluoroquinolone agents, and linezolid were most frequently prescribed. Linezolid was used more often in those with SCCmec II (23.2%) compared to SCCmec IV (18.2%) isolates (\( P = .01 \)) (range per center, 5.6%–34.8%). A single oral antibiotic was prescribed for approximately 7% of treatment events. Rifampin and clindamycin were rarely prescribed. Agents without MRSA activity were prescribed in approximately 7% of treatment events.

Symptoms were recorded at 85.6% of visits in which new antibiotics were prescribed. The number of symptoms was similar for participants with SCCmec II vs SCCmec IV isolates (mean [SD] 3.02 [1.99] vs 2.89 [2.01], respectively, adjusted; \( P = .68 \)). The number of symptoms among SCCmec IV PVL(-) vs PVL(+) isolates was also similar (mean [SD] = 3.01 [2.05] vs 2.76 [1.95], respectively, adjusted; \( P = .67 \)).

### Pulmonary Exacerbations
Study criteria for a pulmonary exacerbation were met in 77.0% of events for which treating clinicians prescribed antibiotics. The annual rate of study-defined exacerbations was higher in those with SCCmec II isolates than those with SCCmec IV isolates (2.9 [95% CI, 2.7–3.0] vs 2.4 [95% CI, 2.2–2.6], respectively; \( P = .0003 \)). After adjusting for sex, age at first MRSA detection, time since initial MRSA detection, study site, and presence of *P. aeruginosa*, the risk for pulmonary exacerbations remained significantly higher among those with SCCmec II than among those with SCCmec IV isolates (adjusted RR = 1.13 [95% CI, 1.01–1.27]; \( P = .03 \)). Among participants infected with SCCmec IV isolates, the rate of exacerbations was higher in those with PVL(-) isolates than those with PVL(+) isolates (annual rate 2.8 [95% CI, 2.5–3.2] vs 2.0 [95% CI, 1.7–2.3], respectively; \( P = .0002 \)). The adjusted risk for exacerbations remained significantly higher among those with PVL(-) isolates (RR = 1.62 [95% CI, 1.28–2.04]; \( P < .0001 \)).

### Lung Function and Growth
Using all spirometry recorded in the National Patient Registry for the duration of the study (independent of antibiotic usage), the estimated annual rate of decline in

### Table 2. Clinic Visits and Antibiotic Treatment by SCCmec Type and PVL Status

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>SCCmec II (N = 199)</th>
<th>SCCmec IV (N = 88)</th>
<th>P Value</th>
<th>SCCmec IV PVL(+) (N = 50)</th>
<th>SCCmec IV PVL(-) (N = 38)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinic visits/participant</td>
<td>Mean (SD)</td>
<td>13.3 (7.6)</td>
<td>11.8 (7.6)</td>
<td>.15</td>
<td>9.9 (4.5)</td>
<td>14.3 (9.9)</td>
</tr>
<tr>
<td>Clinic visits/year follow-up</td>
<td>Mean (SD)</td>
<td>6.1 (3.0)</td>
<td>5.8 (2.6)</td>
<td>.40</td>
<td>5.3 (2.0)</td>
<td>6.4 (3.1)</td>
</tr>
<tr>
<td>Visits with inhaled, oral, or IV antibiotics prescribed</td>
<td>1642 (60.6%)</td>
<td>549 (51.8%)</td>
<td>&lt;0.001</td>
<td>271 (50.1%)</td>
<td>278 (53.4%)</td>
<td>.28</td>
</tr>
<tr>
<td>Prescriptions of TMP-SMX* %</td>
<td>33.0</td>
<td>35.0</td>
<td>.37</td>
<td>31.0</td>
<td>39.2</td>
<td>.049</td>
</tr>
<tr>
<td>Prescriptions of fluoroquinolone* %</td>
<td>23.4</td>
<td>25.9</td>
<td>.25</td>
<td>22.9</td>
<td>28.8</td>
<td>.12</td>
</tr>
<tr>
<td>Prescriptions of linezolid* %</td>
<td>23.2</td>
<td>18.2</td>
<td>.01</td>
<td>20.7</td>
<td>15.8</td>
<td>.15</td>
</tr>
<tr>
<td>Prescriptions of tetracycline* %</td>
<td>8.6</td>
<td>7.3</td>
<td>.37</td>
<td>11.4</td>
<td>3.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Prescriptions of rifampin%</td>
<td>4.7</td>
<td>3.8</td>
<td>.47</td>
<td>5.6</td>
<td>2.2</td>
<td>.046</td>
</tr>
<tr>
<td>Prescriptions of clindamycin%</td>
<td>0.2</td>
<td>1.6</td>
<td>&lt;0.001</td>
<td>0.7</td>
<td>2.5</td>
<td>.18</td>
</tr>
<tr>
<td>Prescriptions of non-MRSA active oral antibiotic*%</td>
<td>6.9</td>
<td>8.0</td>
<td>.39</td>
<td>7.8</td>
<td>8.3</td>
<td>.88</td>
</tr>
</tbody>
</table>

Abbreviations: IV, intravenous; MRSA, methicillin-resistant *Staphylococcus aureus*; PVL, Panton-Valentine-leukocidin; SCCmec, staphylococcal cassette chromosome mec; SD, standard deviation; TMP-SMX, trimethoprim-sulfamethoxazole. Bold text indicates \( P \) Value <0.05.

*Expressed as a percentage of oral antibiotics prescribed.

These were antibiotics classically not considered active for MRSA (eg, amoxicillin).
FEV1% predicted was not significantly different between SCCmec types (P = .73): -1.8% (95% CI: -3.5, -0.1) for SCCmec II compared to -1.2% for SCCmec IV (95% CI: -4.1, 1.7) adjusted for sex, age at first study visit, time since MRSA onset, study site, and presence of P aeruginosa. Among those with SCCmec IV, PVL was not associated with differing rates of decline in FEV1% predicted (P = .88).

Likewise, changes in BMI/weight for length percentile did not differ between the SCCmec types (P = .74): -0.6% per year (95% CI: -2.9, 1.9) for SCCmec II compared to -1.3% per year for SCCmec IV (95% CI, -5.1, 2.5). Body mass index/weight for length percentile per year did not differ by PVL status (P = .97).

DISCUSSION
This is the first multicenter study to analyze the association between chronic infection with different MRSA SCCmec types with clinical outcomes in patients with CF. At the time of enrollment into this study, those participants with SCCmec II isolates were older, had a longer duration of MRSA infection, and were more likely to be coinfected with P aeruginosa. We demonstrated that, when adjusting for these and other covariates known to impact CF lung disease, the rate of exacerbations was higher in participants with SCCmec II isolates compared to those with SCCmec IV isolates. Furthermore, among those with SCCmec IV isolates, the rate of exacerbations was higher in those with PVL(-) isolates than those with PVL(+) isolates. Likewise, the number of CF clinic visits per participant and per year of follow-up was greater in those infected with PVL(-) isolates. Notably, treating clinicians did not know the SCCmec type infecting their patients; thus, treatment decisions were made without consideration of MRSA type. Forty-four percent of our SCCmec IV isolates were PVL negative, which allowed comparison within this group by PVL status. Previous reports in CF showed worse presentation at MRSA onset in PVL(+) MRSA isolates in a case series [29]. Furthermore, PVL has been postulated to be the cause of necrotizing pneumonia in previously healthy people [30]. However, these earlier observations have been questioned in other studies [18]. Our findings do not lend support to PVL(+) isolates causing worse disease in patients with CF.

Although an observational study cannot determine causality, there are several possible explanations for the different outcomes related to PVL status and SCCmec type. Contrary to our hypothesis that PVL positivity would be associated with worse outcomes, we found that SCCmec IV PVL(-) and SCCmec II [all PVL(-)] isolates were associated with more overall CF clinic visits and with more visits at which antibiotics were prescribed, respectively. These outcomes may be affected by bacterial and host aspects in a multifactorial manner. Bacterial factors related to S aureus type with potential impact include antibiotic susceptibilities, virulence factors, or bacterial fitness. Although some non-CF studies show that a higher vancomycin minimal inhibitory concentration has been associated with worse outcomes [31], we did not see vancomycin-resistant or vancomycin-intermediate isolates in this study [22]. Other bacterial factors were not assessed in this study and would only be speculative. In addition, outcomes observed here may be related to host characteristics rather than bacterial virulence. Observational studies of invasive MRSA infections in the United States have reported that the underlying disease severity of the infected individual, rather than the SCCmec type, was the main risk factor associated with mortality [17, 32].

We had hypothesized that the greater number of antibiotic resistance genes in SCCmec II MRSA would impact the choice of antibiotic therapy used to treat pulmonary exacerbations. We have previously shown that the SCCmec II strains were more often resistant to clindamycin and ciprofloxacin compared with the SCCmec IV strains [22]. We found that linezolid was used more often in those with SCCmec type II compared to SCCmec IV, which may be reflective of these differences in antimicrobial susceptibilities. However, this antibiotic should be used with caution because resistance can emerge [33–35], and it may be associated with potentially irreversible side effects including peripheral neuropathy. Our study definition of exacerbations included the use of oral agents as well as IV antibiotics; this definition allowed assessment of all exacerbations and reduced the potential bias toward more severe events and only very resistant isolates, which were expected to be more frequent in SCCmec II strains.

We acknowledge some limitations of this study. First, only 1 culture was used for classification of MRSA type; however, previous studies, including our own, have shown persistence of the same strain over time [36–38]. In addition, although this was a multicenter study, inclusion was limited to children, and it is unknown whether these findings are generalizable to adults, or to CF centers that have a prevalence of MRSA less than 20%, or to children with CF outside the United States, where different strains may be prevalent. Duration of follow-up was variable for the participants; however, there were not significant differences between groups, and our analysis accounted for follow-up duration; therefore, results are unlikely biased. Longitudinal spirometry and weight for length/BMI were compared, and no differences by
SCCmec type or PVL were observed, despite differences in pulmonary exacerbations. We speculated that these observations may reflect several factors related to this study design and population. The FEV1% predicted and BMI percentiles in the Patient Registry had high a within-patient variation. In addition, 16% of the population was too young to reliably perform spirometry at study entry, whereas they were included in the exacerbation analysis. Furthermore, published studies of the association between lung function decline and exacerbations typically define exacerbations as events when IV antibiotics were used. In this study, however, exacerbations were also defined when oral antibiotics were used, which may have prevented lung function decline. The estimated rate of FEV1 decline in this cohort was consistent with previously reported declines in lung function among CF patients persistently infected with MRSA [5]. Another possible source of bias is the fact that patient signs and symptoms were only collected when new antibiotics were prescribed, both to limit reporting burden to the sites and because we considered symptoms not associated with treatment to be relatively minor in scope. However, in this pediatric population, there may be an overall lower threshold for treating as seen by use of antibiotics in 23% of cases that did not meet exacerbation criteria. Lastly, we chose not to collect antibiotic susceptibilities for isolates tested at each visit and each study site to avoid variation in techniques and results; thus, study outcomes were not analyzed by success or failure of antibiotic course.

CONCLUSIONS

In conclusion, we show that children with CF chronically infected with SCCmec II MRSA isolates have higher exacerbation rates and use of oral antibiotics compared with those with SCCmec IV and that PVL(+) status was not associated with worse outcome. Although an epidemiologic study cannot address causality of higher exacerbation rates, our results do raise the following questions: (1) would routine clinical typing be advantageous to clinicians treating patients chronically infected with MRSA? and (2) are further, prospective studies that include subtyping warranted? The answers to these questions could allow us to more precisely direct care and to determine whether an eradication strategy should be favored based on S. aureus type. Currently, data showing the benefit of early eradication for any MRSA type in CF are not available, but studies examining the clinical effect of eradication are in progress.

Acknowledgments

We acknowledge Emily Knapp and the Cystic Fibrosis Foundation for providing patient-specific data from the US Cystic Fibrosis Patient Registry. We also gratefully acknowledge the anonymous referees whose thoughtful reviews improved this manuscript.

Author contributions. The listed authors provided direct contribution to this manuscript. Investigators from the other study STAR-CF sites were involved in sample collection, study-related conference calls, and read the manuscript.

Financial support. This work was supported by Cystic Fibrosis Foundation Therapeutics (Grant MUHLEB08A0; to M. S. M., S. L. H., M. K., V. T., and study sites) and the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases (Grant P30DK089507; to S. L. H.).

Potential conflicts of interest. M. S. M. has received research funding from Cystic Fibrosis Foundation for this project as stated in the financial support statement. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References
